Hungarian drugmaker Richter Gedeon said that the 41% slump in its half year profits, to 18.5 billion forint ($101.3 million), which was in line with forecasts, was a result of an 8.4% drop, to 27.1 billion forint, in domestic sales.
Richter said that the decline, which was despite an 11.5% increase in export revenues to 86.3 billion forint, was a result of domestic price cuts, necessary to keep certain products on the Hungarian reimbursement list. The firm added that it was raising export targets for the rest of the year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze